Boston Biomedical, Inc. focuses on the research and development of cancer therapeutics. Its product pipeline comprises BBI608 is an orally-administered investigational agent designed to inhibit cancer stem cell pathways by targeting STAT3; and BBI503, an orally-administered investigational agent designed to inhibit Nanog and other cancer stem cell pathways by targeting kinases. The company was founded in 2006 and is based in Cambridge, Massachusetts. As of April 24, 2012, Boston Biomedical, Inc. operates as a subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
640 Memorial Drive
Cambridge, MA 02139
Founded in 2006
Boston Biomedical Announces Clinical Data on the Investigational Compounds BBI608 and BBI503
Jun 1 15
Boston Biomedical announced that it will present clinical data on the investigational compounds BBI608 and BBI503 in multiple tumor types at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Data presented at ASCO highlight the potential of BBI608 -- an orally-administered investigational agent that targets STAT3, leading to inhibition of the critical genes for maintaining cancer stemness -- for anti-cancer activity when used in combination with other chemotherapeutics across varying advanced cancers, including gastric and colorectal. Additionally, as part of the "trials in progress" program, the study protocol from the BRIGHTER study, a phase 3 clinical trial currently underway to investigate cancer stem cell pathway inhibition, is also showcased. Additional data featuring BBI503 -- an orally-administered investigational agent designed to inhibit Nanog and other cancer stem cell pathways by targeting kinases -- showed encouraging early signs of anti-cancer activity for patients with advanced colorectal cancer. Boston Biomedical poster presentations include: Abstract #4069, Poster #179: BBI608-201: Phase 1b/2 study of cancer stemness inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Data from the study showed BBI608 and weekly paclitaxel can be combined in patients with advanced pre-treated gastric/GEJ cancer. Lesion regression, objective responses, and prolonged stable disease were observed in heavily pre-treated patients. In evaluable patients who had not previously received a taxane in the metastatic setting, and who received one prior line of therapy (n=6), namely the patients that meet the enrollment criteria for the BRIGHTER trial, an objective response rate (ORR) of 50% was observed. In heavily pretreated patients (failed average >2 lines of prior therapies) who had not previously received a taxane in the metastatic setting (n=16), the ORR was 31% in the per-protocol population. The disease control rate (DCR) was 75%; median progression-free survival (mPFS) was 20.6 weeks and median overall survival (mOS) was 39.3 weeks. Most common adverse events were grade 1 to 2 diarrhea, nausea, vomiting and abdominal pain. Grade 3 adverse events included vomiting (8.7%), diarrhea of 5 days or longer (6.5%), fatigue (6.5%), abdominal and gastrointestinal pain, nausea, dehydration, anorexia, white blood cell decrease and acute kidney injury (2.2% each). Continued evaluation of this combination and patient population, specifically in those patients who received one prior line of therapy, is currently underway in the phase 3 BRIGHTER study. Abstract #TPS4139, Poster #247a: The BRIGHTER trial: A phase 3 randomized, double-blind, placebo-controlled clinical trial of first-in-class cancer stemness inhibitor BBI608 plus weekly paclitaxel versus placebo plus weekly paclitaxel in adult patients with advanced, previously treated gastric and gastro-esophageal junction (GEJ) adenocarcinoma. The goal of the BRIGHTER trial (NCT02178956) is to determine if BBI608 given together with paclitaxel as second-line therapy will extend survival compared to treatment with paclitaxel alone. Enrollment is ongoing at multiple sites in North America, Europe, Australia and Japan. BBI608 blocks cancer stem cell renewal and survival by suppressing stemness pathways, including STAT3, beta-catenin and immune checkpoint gene expression. Abstract #3616, Poster #109: BBI608-246: A phase 1b study of first-in-class cancer stemness inhibitor BBI608 in combination with FOLFIRI with and without Bevacizumab in patients with advanced colorectal cancer. Data from the study showed that BBI608 at 240 mg BID can be combined with FOLFIRI, with or withoutbevacizumab, in patients with advanced and heavily pretreated colorectal cancer (CRC). Disease control, measured by partial response and stable disease, was observed in 100% of evaluable patients (n=9), including 6 patients who had failed FOLFIRI previously, with partial response in 2/9 patients and stable disease in 7/9 patients, all of whom (9/9 patients) experienced signs of tumor regression. Prolonged stable disease (more than or equal to 6 months) was observed in 5/9 patients (55.6%) of evaluable patients. The median progression-free survival was 23.7 weeks. Abstract #3617, Poster #110: BBI608-224: A phase 1b/2 study of cancer stemness inhibitor BBI608 administered with Panitumumab in KRAS wild-type patients with metastatic colorectal cancer. Results from the study found that BBI608 and bi-weekly panitumumab can be combined at the full dose of 480-500 mg BID. Abstract #3615, Poster #108: BBI503-101: Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer. The findings indicated that BBI503 as a monotherapy was tolerated at the recommended phase 2 dose of 300 mg once daily.
Boston Biomedical, Inc. and Boston Biomedical Pharma Inc. Appoint Patricia S. Andrews as Executive Vice President and Chief Commercial Officer
Nov 14 13
Boston Biomedical, Inc. and Boston Biomedical Pharma Inc., collectively "Boston Biomedical", announced that it has appointed Patricia S. Andrews as Executive Vice President and Chief Commercial Officer as it begins strategic planning and preparations for the commercialization of its cancer stem cell inhibitors with its lead asset, BBI608, currently in a global Phase 3 clinical trial for metastatic colorectal cancer. Ms. Andrews most recently served as Executive Vice President and Chief Commercial Officer at Incyte Corporation.